# NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

> **NCT06128213** · PHASE2 · UNKNOWN · sponsor: **NeuroRx, Inc.** · enrollment: 13 (estimated)

## Conditions studied

- Urinary Tract Infections
- Pyelonephritis

## Interventions

- **DRUG:** NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))

## Key facts

- **NCT ID:** NCT06128213
- **Lead sponsor:** NeuroRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-31
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128213, "NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06128213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*